Metastasis is one of the main causes of failure in the treatment of triple-negative breast cancer (TNBC). Immunotherapy brings hope and opportunity to solve this challenge, while its clinical applications are greatly inhibited by the tumor immunosuppressive environment. Here, an intelligent biomimetic nanoplatform was designed based on dendritic large-pore mesoporous silica nanoparticles (DLMSNs) for suppressing metastatic TNBC by combining photothermal ablation and immune remodeling. Taking advantage of the ordered large-pore structure and easily chemically modified property of DLMSNs, the copper sulfide (CuS) nanoparticles with high photothermal conversion efficiency were in situ deposited inside the large pores of DLMSNs, and the immune adjuvant resiquimod (R848) was loaded controllably. A homogenous cancer cell membrane was coated on the surfaces of these DLMSNs, followed by conjugation with the anti-PD-1 peptide AUNP-12 through a polyethylene glycol linker with an acid-labile benzoic-imine bond. The thus-obtained AM@DLMSN@CuS/R848 was applied to holistically treat metastatic TNBC in vitro and in vivo. The data showed that AM@DLMSN@CuS/R848 had a high TNBC-targeting ability and induced efficient photothermal ablation on primary TNBC tumors under 980 nm laser irradiation. Tumor antigens thus generated and increasingly released R848 by response to the photothermal effect, combined with AUNP-12 detached from AM@DLMSN@CuS/R848 in the weakly acidic tumor microenvironment, synergistically exerted tumor vaccination, and T lymphocyte activation functions on immune remodeling to prevent TNBC recurrence and metastasis. Taken together, this study provides an intelligent biomimetic nanoplatform to enhance therapeutic outcomes in metastatic TNBC.

No abstract

No abstract

No abstract

a: Cuckoo flew down to target nest; b: Host guarded nest; c: Cuckoo perched on target nest; d: Cuckoo hid its head and started egg pecking/biting; e: Cuckoo hunched its body, pecked an egg, closed its tail, and opened its eyes; f: Cuckoo finished egg laying, sometimes removing an egg; g: Cuckoo flew away.

No abstract

Dendritic large-pore mesoporous silica nanoparticles (DLMSN) is an important biodegradable drug carrier due to its high porosity, which can be prepared by coassembly of a major template and an auxiliary template in aqueous solution, followed by hydrolysis of tetraethyl orthosilicate (TEOS). The auxiliary template is key to obtaining dendritic large-pore structures; however, how to choose the auxiliary template to obtain the desired pore structure is largely unknown. This is because the formation mechanism of DLMSN is still not clear. In this study, a series of therapeutic agent molecules were used as the auxiliary templates to study the control of the pore morphology of DLMSN. Transmission electron microscopy observation and theoretical modeling were used to study the micelle formation, and early stage silica formation was also observed. It is proposed that the silica branches and sheets formed by hydrolysis of TEOS on single micelle and micelle bundles, which formed the initial nanoparticles with spherical structures and new silica species growing on the early formed particles to form DLMSN. The fine control of pore morphology was demonstrated by using auxiliary templates with different structural characteristics, which were used for selective drug loading. This work provides a design strategy of how to choose suitable auxiliary templates for preparing DLMSN with desired pore structure for biomedical applications.

The epidemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has increasingly attracted worldwide concern. Liver damage or dysfunction occurred in patients with COVID-19 (mainly characterized by moderately elevated serum aspartate aminotransferase levels). However, it is not yet clear whether the COVID-19-related liver injury is mainly caused by the virus infection, potentially hepatotoxic drugs, or other coexisting conditions. Progression of pre-existing chronic liver disease (CLD) may be the underlying mechanism of liver injury. Although COVID-19 patients with CLD, such as nonalcoholic fatty liver disease, liver cirrhosis, and liver cancer, have been deemed at increased risk for serious illness in many studies, little is known about the impact of CLD on the natural history and outcome of COVID-19 patients. Thereby, based on the latest evidence from case reports and case series, this paper discusses the clinical manifestations, treatment, prognosis, and management of the COVID-19 patients with different CLD. This article also reviews the effect of COVID-19 on liver transplantation patients (LT), hoping to work for future prevention, management, and control measures of COVID-19. However, due to the lack of relevant research, most of them are still limited to the theoretical stage, further study of COVID-19 and CLD needs to be improved in the future.